Side-by-side · Research reference
GHK-CuvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticReviewed8/47 cited
BFDA-ApprovedReviewed13/41 cited
GHK-Cu
Tripeptide · Skin / Hair / Wound Healing
SQ or topical · Local · Daily or 2-3×/week
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
GHK-Cu
PT-141
Primary target
Copper-dependent enzymes (lysyl oxidase, SOD); regulator of >4000 human genesPickart 2018
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Cu(II) delivery via GHK chelation → ↑collagen / elastin / GAG synthesis; ↓inflammatory cytokines; ↑hair follicle growth-factor signalingPickart 2018
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Skin firmness + texture improvement, accelerated wound healing, hair regrowth, anti-inflammatory actionPickart 2018Zink 2003
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
Replaces declining endogenous levels
—
Origin
Endogenous tripeptide first isolated from human plasma; declines from ~200 ng/mL at age 20 to ~80 ng/mL at age 60Pickart 2018
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
GHK-Cu
PT-141
Standard SQ dose
1–2 mg / dayPickart 2018
Anecdotal injectable range; topical creams use 0.1–2% solutions.
—
Topical concentration
0.1–2.0% in serum / cream
—
Frequency
Daily or 2–3× per week (SQ)
PRN, max 8 doses / month
Lower / starter dose
0.5 mg / day SQ
1 mg (off-label)
Evidence basis
Human-mechanistic + topical clinical studiesPickart 2018
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
8–12 weeks for visible skin / hair effect
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water; light-protected
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
No specific time; evening preferred for topicals
≥45 min before sexual activity
Standard dose
—
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
04Side Effects & Safety
Parameter
GHK-Cu
PT-141
Injection site reaction
Erythema, mild pruritus (common)
Erythema, mild pain
Topical irritation
Mild redness, transient stinging
—
Copper accumulation
Theoretical with very high chronic doses
—
Allergic reaction
Rare hypersensitivity to copper
—
Pregnancy / OB
Avoid topical and SQ — insufficient data
Contraindicated
Wilson disease
Contraindicated
—
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
GHK-Cu
- ·Wilson disease (copper-overload disorder)
- ·Pregnancy / breastfeeding
- ·Known copper hypersensitivity
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
GHK-Cu
- ·Hemochromatosis (copper-iron crosstalk theoretical)
- ·Concurrent copper-chelator therapy
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
GHK-Cu
PT-141
1. Reconstitution
Add 1–2 mL bacteriostatic water to a 50 mg vial → 25–50 mg/mL. Use within 30 days, refrigerated.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
SQ — local to the area of interest (face, scalp) for skin / hair indications. Rotate sites.
SQ — abdomen or thigh.
3. Timing
Anytime; evening preferred. Topical: apply to clean dry skin.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, light-protected, ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
30–31G, short (4–6 mm) for shallow SQ. Topical: clean fingertips, no needle.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.
06Stack Synergy
GHK-Cu
+ BPC-157
ModerateGHK-Cu drives ECM remodelling and copper-dependent enzymes; BPC-157 upregulates VEGFR2 angiogenesis and fibroblast migration. The pathways are non-overlapping and complementary — together they accelerate wound healing more than either alone in anecdotal protocols.
- GHK-Cu
- 1–2 mg SQ · daily near wound
- BPC-157
- 250–500 mcg SQ · daily near wound
- Primary benefit
- Combined ECM rebuilding + angiogenesis for tissue repair
PT-141
— no documented stacks